Outcome | Placebo | SP* | Protective efficacy | p | ||||
---|---|---|---|---|---|---|---|---|
Events | PYAR | Rate | Events | PYAR | Rate | (95% CI) | ||
During 1 month after dose 1 | ||||||||
Ifakara | 8 | 21.71 | 0.37 | 1 | 22.21 | 0.05 | 87.8% (2.3;98.5) | 0.012 |
Manhiça | 13 | 47.48 | 0.27 | 1 | 49.97 | 0.02 | 92.7% (44.2;99.0) | < 0.001 |
Combined effect adjusted by study | 21 | 69.19 | 0.30 | 2 | 72.18 | 0.03 | 90.9% (61.0;97.9) | < 0.001 |
During 1 month after dose 2 | ||||||||
Ifakara | 6 | 21.83 | 0.27 | 0 | 22.41 | 0.00 | 100% (.;100) | 0.004 |
Manhiça | 23 | 47.33 | 0.49 | 10 | 50.27 | 0.20 | 59.0% (13.8;80.5) | 0.014 |
From 1 month after dose 2 until dose 3 | ||||||||
Ifakara | 32 | 100.08 | 0.32 | 16 | 106.04 | 0.15 | 52.8% (14.0;74.1) | 0.011 |
Manhiça | 92 | 169.09 | 0.54 | 85 | 183.36 | 0.46 | 14.7% (-14.6;36.5) | 0.292 |
During 1 month after dose 3 | ||||||||
Ifakara | 14 | 21.51 | 0.65 | 2 | 22.32 | 0.09 | 86.2% (39.4;96.9) | 0.001 |
Manhiça | 32 | 46.94 | 0.68 | 16 | 49.82 | 0.32 | 52.7% (13.9;74.1) | 0.012 |
During 6 months from 1 month after dose 3 | ||||||||
Ifakara | 51 | 112.56 | 0.45 | 37 | 120.90 | 0.31 | 32.2% (-3.5;55.6) | 0.070 |
Manhiça | 107 | 228.31 | 0.47 | 104 | 239.31 | 0.43 | 7.4% (-21.3;29.3) | 0.578 |